Strefen / Reckitt Benckiser - LARVOL DELTA

Comparative Effects of Flurbiprofen and Benzydamine on COX-2/PGE2 and Inflammatory Cytokine Release in Polyinosinic:polycytidylic Acid-Stimulated Human Tonsil and Bronchial Epithelial Cells. (PubMed, Int J Mol Sci) - "Benzydamine showed limited or no effect and less inhibition of caspase-1. With rapid suppression of the COX-2/PGE2 pathway, rapid onset and a broad inhibition spectrum, flurbiprofen more comprehensively modulates inflammatory processes in epithelial respiratory models."

Clinical • Journal • Infectious Disease • Oncology • CXCL10 • CXCL8 • IL18 • IL1B • IL6 • PTGS2 • TNFA

Development and refinement of the sore throat pain model as an assay for measuring therapeutic effects on acute pain. (PubMed, Front Pain Res (Lausanne)) - "As such, the condition has served as a general acute pain model to demonstrate the acute effects of non-prescription-strength analgesic agents (for mild-to-moderate pain) and prescription-strength analgesics (for moderate-to-severe pain). Here we discuss the methodologic features of this clinical pharmacology assay as it was refined from its original examinations of classic, orally administered, acute analgesics (aspirin, acetaminophen, aspirin with caffeine, ibuprofen) to its more recent evaluations of celecoxib, valdecoxib, topical benzydamine, and topical flurbiprofen."

Clinical • Journal • Review • Otorhinolaryngology • Pain • Respiratory Diseases

Effect of Over-the-counter NSAIDS on Cough Reflex Sensitivity in Patients with Upper Respiratory Tract Infections (clinicaltrials.gov) - P1 | N=101 | Completed | Sponsor: University of Melbourne | Recruiting ➔ Completed

Reflex • Trial completion • Cough • Infectious Disease • Respiratory Diseases

Role of In Vitro Tests in the Characterisation of Locally Applied, Locally Acting Drugs in the Throat: Application to Flurbiprofen. (PubMed, Pharmaceutics) - "Rheological evaluations further demonstrated that the mucoadhesive properties of the gel spray formulation are based on interaction with mucin. Designing a relevant in vitro test requires adequate evaluation of the complexity of the drug substance, drug product, dosing conditions and delivery processes."

Journal • Preclinical

A systematic review of flurbiprofen 8.75 mg dose and risk of adverse events (excluding haemorrhagic) resulting from drug-drug interactions. (PubMed, Front Pharmacol) - " Results from this systematic review on the risk of non-haemorrhagic events did not provide evidence for these events occurring as a result of interaction with other medicinal products. Additional appropriately designed studies would be required to confirm whether these findings suggest a true absence of risk or limitations in reporting."

Adverse events • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Otorhinolaryngology

Relationship between Pharmacokinetic Profile and Clinical Efficacy Data of Three Different Forms of Locally Applied Flurbiprofen in the Mouth/Throat. (PubMed, Pharmaceutics) - "These pAUCs provide useful data that allow for the discrimination between formulations. Moreover, the pAUC values represent <5% of the total AUC, suggesting that the early onset of pain relief is a response to immediate local absorption at the site of action rather than a systemic effect."

Journal • PK/PD data • Otorhinolaryngology • Pain

Effect of Over-the-counter NSAIDS on Cough Reflex Sensitivity in Patients With Upper Respiratory Tract Infections (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: University of Melbourne

New P1 trial • Cough • Infectious Disease • Respiratory Diseases

Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection. (PubMed, Int J Mol Sci) - "Ibuprofen, flurbiprofen, etoricoxib and paracetamol demonstrated no effects on ACE2 expression or activity in vitro or in vivo. Higher concentrations of ibuprofen and flurbiprofen reduced SARS-CoV-2 replication in vitro."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Systematic Review of Flurbiprofen 8.75 mg Dose and Risk of Haemorrhagic Events. (PubMed, Front Pharmacol) - "Counts were low across all studies and results comparing flurbiprofen and placebo treatment arms were non-significant. However, scarcity of studies and low certainty of evidence for the outcome of haemorrhagic events limits the conclusions of this systematic review."

Journal • Review • Otorhinolaryngology

Evidence of the Efficacy of Flurbiprofen 8.75 mg Lozenges for Patients Receiving Antibiotics for Laboratory-Confirmed Streptococcal Pharyngitis. (PubMed, Ear Nose Throat J) - "Irrespective of antibiotic use, flurbiprofen 8.75 mg lozenges provide well-tolerated, effective relief of pharyngeal symptoms in patients with streptococcal infection. In the 24 hours after administration, antibiotics provide no relief of throat pain or difficulty swallowing beyond the topical demulcent effects of placebo lozenges."

Clinical • Journal • Infectious Disease • Otorhinolaryngology • Pain • Respiratory Diseases